Understanding Idelvion: A Comprehensive Guide to Hemophilia B Treatment

Introduction to Idelvion

Hemophilia B is a rare, inherited bleeding disorder characterized by a deficiency or defect in coagulation Factor IX, a protein essential for blood clotting. This deficiency leads to prolonged bleeding episodes, which can be spontaneous or result from injury or surgery. For individuals living with Hemophilia B, effective treatment is crucial to prevent life-threatening hemorrhages and improve quality of life. Idelvion, also known as Coagulation Factor IX (Recombinant), Albumin Fusion Protein, represents a significant advancement in the management of Hemophilia B. It is a long-acting recombinant Factor IX replacement therapy designed to provide sustained protection against bleeding episodes, thereby reducing the frequency of infusions required for prophylaxis.

This comprehensive guide will delve into what Idelvion is, the underlying condition of Hemophilia B, how Idelvion works at a molecular level, its approved uses, detailed dosage and administration protocols, potential side effects, important precautions, and when to consult a healthcare professional. Our goal is to provide a clear, factual, and accessible resource for patients, caregivers, and anyone seeking to understand this vital medication and its role in modern hemophilia care.

Understanding Hemophilia B: A Deeper Dive

Hemophilia B, also known as Christmas disease, is a genetic disorder that primarily affects males, although females can be carriers and, in rare instances, may exhibit mild symptoms. It is an X-linked recessive disorder, meaning the gene responsible for producing Factor IX is located on the X chromosome. A mutation in the F9 gene prevents the body from making enough functional Factor IX, a crucial component of the intrinsic pathway of the coagulation cascade.

Genetic Basis and Inheritance

The F9 gene mutation can range from small deletions or insertions to larger rearrangements, leading to varying degrees of Factor IX deficiency. Since males have one X and one Y chromosome, a single mutated F9 gene on their X chromosome will result in Hemophilia B. Females, with two X chromosomes, typically need a mutated F9 gene on both X chromosomes to manifest the disease, which is exceedingly rare. More commonly, females are carriers, possessing one mutated and one normal F9 gene. Carriers may have slightly reduced Factor IX levels and, in some cases, experience mild bleeding symptoms, especially during surgery or after trauma.

Clinical Presentation and Symptoms

The severity of Hemophilia B is directly correlated with the level of functional Factor IX activity in the blood:

• Severe Hemophilia B: Less than 1% Factor IX activity. Individuals experience frequent spontaneous bleeding, often into joints (hemarthrosis) and muscles, starting early in childhood. This can lead to chronic pain, joint damage, and disability.
• Moderate Hemophilia B: 1% to 5% Factor IX activity. Bleeding episodes are less frequent and usually occur after minor injuries, trauma, or surgery. Spontaneous bleeds are less common than in severe cases.
• Mild Hemophilia B: 6% to 40% Factor IX activity. Bleeding usually occurs only after significant injury, surgery, or major trauma. Many individuals with mild hemophilia may not be diagnosed until later in life.

Common bleeding manifestations include:

• Hemarthrosis: Bleeding into joints (knees, elbows, ankles) causing pain, swelling, warmth, and reduced range of motion. Repeated hemarthrosis leads to chronic arthropathy.
• Muscle Hematomas: Bleeding into muscles, causing pain, swelling, and potential nerve compression.
• Mucocutaneous Bleeding: Nosebleeds, gum bleeding, easy bruising.
• Intracranial Hemorrhage: A life-threatening complication, especially in infants, requiring immediate medical attention.
• Other Internal Bleeding: Bleeding in the gastrointestinal tract, kidneys, or other organs, which can be difficult to detect and manage.

Diagnosis of Hemophilia B

Diagnosis typically involves a combination of laboratory tests:

1. Screening Tests: Activated partial thromboplastin time (aPTT) will be prolonged, indicating a problem in the intrinsic pathway. Prothrombin time (PT) and bleeding time are usually normal.
2. Specific Factor Assays: A Factor IX activity assay measures the amount of functional Factor IX in the blood, confirming the diagnosis and determining severity.
3. Genetic Testing: DNA sequencing can identify the specific mutation in the F9 gene, which is useful for genetic counseling, carrier identification, and prenatal diagnosis.

Complications of Hemophilia B

Beyond acute bleeding, long-term complications can significantly impact quality of life:

• Chronic Arthropathy: Permanent joint damage from recurrent hemarthrosis.
• Inhibitor Development: The immune system may develop antibodies (inhibitors) against the infused Factor IX, rendering treatment ineffective. This is a serious complication requiring specialized management.
• Viral Infections: Historically, plasma-derived treatments carried a risk of viral transmission (e.g., HIV, hepatitis). Recombinant products like Idelvion have largely eliminated this risk.

Idelvion's Mechanism: The Science Behind the Extended Half-Life

Idelvion is a recombinant DNA-derived coagulation Factor IX product, meaning it is manufactured in a controlled laboratory setting using genetically engineered cells, specifically human embryonic kidney (HEK 293) cells. This production method ensures a consistent, high-quality product free from human plasma components, thereby eliminating the risk of transmitting human blood-borne viruses.

The Coagulation Cascade and Factor IX

In the normal process of hemostasis, Factor IX is a pivotal enzyme. When activated (Factor IXa), it forms a complex with activated Factor VIII (Factor VIIIa), calcium ions, and phospholipids on a cell surface. This 'tenase complex' is critical for efficiently activating Factor X, which then proceeds to activate prothrombin into thrombin. Thrombin, in turn, converts fibrinogen into fibrin, forming a stable clot that stops bleeding. In Hemophilia B, the absence or dysfunction of Factor IX breaks this chain, leading to impaired clot formation.

The Albumin Fusion Protein Advantage

The unique feature of Idelvion is its fusion with recombinant albumin. Albumin is the most abundant protein in human plasma and plays a crucial role in maintaining osmotic pressure and transporting various substances. Importantly, albumin has a naturally long half-life in the body, primarily due to its interaction with the neonatal Fc receptor (FcRn). The FcRn receptor protects albumin from degradation and recycles it back into circulation.

By genetically fusing Factor IX to recombinant albumin, Idelvion leverages albumin's extended half-life characteristics. This fusion results in a molecule that:

• Has a Significantly Extended Half-Life: Idelvion's half-life is approximately 102 hours, which is about 5 times longer than conventional (non-modified) recombinant Factor IX products. This extension is primarily due to reduced renal clearance and increased recycling via the FcRn pathway, similar to albumin itself.
• Provides Sustained Factor IX Activity: The prolonged presence of functional Factor IX in the bloodstream ensures a more consistent and sustained protective level against bleeding, allowing for less frequent infusions.
• Maintains Full Biological Activity: Despite the fusion, the Factor IX component of Idelvion retains its full procoagulant activity, effectively replacing the deficient natural Factor IX.

Once administered intravenously, Idelvion circulates, binds to the FcRn receptor, and is recycled, leading to its prolonged presence and sustained therapeutic effect, thereby enabling the body's coagulation system to respond effectively to bleeding challenges.

Therapeutic Applications of Idelvion

Idelvion is a versatile treatment approved for various aspects of Hemophilia B management in both adults and children.

1. Routine Prophylaxis to Prevent Bleeding

This is the cornerstone of modern hemophilia care, especially for individuals with severe and moderate Hemophilia B. Regular, scheduled infusions of Idelvion are administered to maintain sufficiently high Factor IX levels in the blood, thereby preventing spontaneous bleeding episodes. The extended half-life of Idelvion offers significant advantages in this setting, allowing for less frequent infusions – typically once every 7, 10, or 14 days. This reduced frequency can substantially improve patient adherence to treatment regimens, reduce the burden of frequent injections, and enhance overall quality of life by providing greater flexibility and freedom.

2. On-Demand Treatment and Control of Bleeding Episodes

Despite prophylactic treatment, breakthrough bleeding can occur, or patients may require treatment for acute bleeding episodes resulting from injuries, trauma, or spontaneous hemorrhages. Idelvion can be administered to rapidly increase Factor IX levels to stop active bleeding. The dose and frequency depend on the severity and location of the bleed, with higher doses typically used for more serious or life-threatening hemorrhages. Prompt treatment of bleeding is crucial to minimize damage and prevent long-term complications.

3. Perioperative Management (Surgical Prophylaxis)

For individuals with Hemophilia B undergoing surgical procedures (ranging from minor dental work to major operations), Idelvion is used to prevent excessive bleeding during and after surgery. This involves administering a dose prior to the procedure to achieve target Factor IX levels and often includes repeat dosing during the post-operative period to maintain hemostasis until the wound has healed adequately. Careful planning and monitoring by a multidisciplinary team are essential for safe surgical outcomes.

Administering Idelvion: A Practical Guide

Idelvion is administered intravenously (into a vein) after it has been reconstituted from its lyophilized (freeze-dried) powder form. The dosage and frequency of administration are highly individualized and must be determined by a physician experienced in treating hemophilia. Factors influencing dosing include the patient's body weight, the severity of their Factor IX deficiency, the type and location of the bleeding event, and the desired Factor IX activity level.

How Idelvion is Supplied

Idelvion is typically supplied as a kit containing:

• A single-dose vial of Idelvion lyophilized powder.
• A pre-filled syringe of sterile water for injection (diluent).
• A vial adapter (e.g., BAXJECT III) for reconstitution.
• An administration set, including a sterile venipuncture set and alcohol swabs.

Reconstitution Process

Accurate and aseptic reconstitution is critical. Patients or caregivers trained for home infusion must follow these steps precisely:

1. Preparation: Gather all necessary supplies. Wash hands thoroughly with soap and water. Ensure a clean, flat work surface.
2. Warm Diluent: Allow the pre-filled syringe of sterile water to reach room temperature.
3. Prepare Vials: Remove plastic caps from the Idelvion powder vial and the diluent syringe. Wipe the rubber stoppers of both vials with alcohol swabs and allow to dry.
4. Attach Vial Adapter: Twist the vial adapter onto the diluent syringe.
5. Connect to Powder Vial: Place the Idelvion powder vial on a flat surface. Invert the diluent syringe with the attached adapter and push the adapter spike firmly through the center of the powder vial stopper.
6. Reconstitute: Slowly inject the diluent into the powder vial. The powder will dissolve. Do not shake the vial forcefully; gently swirl it until the powder is completely dissolved. The solution should be clear to slightly opalescent and colorless to slightly yellowish. Do not use if it contains visible particles or is discolored.
7. Withdraw Solution: Once reconstituted, invert the vial and slowly draw the solution into the syringe.

Intravenous Administration

The reconstituted Idelvion solution should be administered intravenously immediately or within 3 hours after reconstitution. It should not be refrigerated after reconstitution. The infusion rate should be slow and comfortable for the patient, typically not exceeding 10 mL per minute. Patients trained for self-infusion at home must strictly adhere to aseptic techniques to prevent bloodstream infections. Proper disposal of all used materials is also essential.

Dosing Guidelines and Personalization

Idelvion dosing is highly personalized. Your doctor will establish a treatment plan based on your specific needs:

• Routine Prophylaxis: Common starting doses range from 35 to 75 IU/kg, administered once weekly, once every 10 days, or once every 14 days. The interval and dose are adjusted based on individual patient response, bleed frequency, Factor IX trough levels, and pharmacokinetic (PK) parameters.
• On-Demand Treatment: Dosing for bleeding episodes is calculated to achieve a target Factor IX activity level depending on the severity and location of the bleed. For example, minor bleeds might require raising Factor IX to 20-40% of normal, while major bleeds might require 80-100%.
• Perioperative Management: Pre-operative doses are calculated to achieve target Factor IX levels (e.g., 50-100% for major surgery). Subsequent doses are given to maintain these levels throughout the surgical and post-operative recovery period.

Regular monitoring of Factor IX activity levels through laboratory tests is crucial to ensure adequate therapeutic effect, adjust dosing as needed, and detect any potential development of Factor IX inhibitors.

Navigating Potential Side Effects of Idelvion

Like all medications, Idelvion can cause side effects, although not everyone experiences them. It is important for patients and caregivers to be aware of potential reactions and to report any concerns to their healthcare provider.

Common Side Effects

The most commonly reported side effects observed in clinical trials, which are generally mild and transient, include:

• Headache: Often mild and can be managed with over-the-counter pain relievers.
• Dizziness: Usually temporary and resolves on its own.
• Injection Site Reactions: Such as pain, redness, swelling, or itching at the infusion site. These are typically localized and mild.
• Nausea: Can occur during or after infusion.
• Rash: Often mild and transient.
• Fever: Low-grade fever may occur.
• Pruritus (Itching): Generalized itching or itching at the infusion site.

If these side effects persist, worsen, or become bothersome, contact your doctor for advice.

Serious Side Effects: When to Seek Immediate Medical Attention

While rare, more serious adverse reactions can occur. It is crucial to recognize the signs and seek immediate medical attention if you experience any of the following:

1. Hypersensitivity and Anaphylactic Reactions

Severe allergic reactions are a potential risk with any protein-based product. Symptoms can develop rapidly during or after infusion and may include:

• Skin Reactions: Generalized hives (urticaria), widespread rash, intense itching (pruritus).
• Respiratory Distress: Difficulty breathing, wheezing, shortness of breath, chest tightness, or throat constriction.
• Cardiovascular Symptoms: Dizziness, lightheadedness, fainting, rapid heart rate, or a sudden drop in blood pressure.
• Swelling: Swelling of the face, lips, tongue, or throat (angioedema).

If any of these symptoms occur, stop the Idelvion infusion immediately and seek emergency medical care. Patients with a known history of severe allergic reactions to Factor IX products or components of Idelvion should discuss this thoroughly with their physician. Epinephrine and other appropriate medical therapies should always be readily available during infusions.

2. Thromboembolic Events (Blood Clots)

There is a potential risk of blood clot formation (thrombosis) with Factor IX products, particularly in patients with pre-existing risk factors or those receiving high doses. Symptoms of a blood clot can vary depending on its location and may include:

• Deep Vein Thrombosis (DVT): Pain, swelling, warmth, and redness in an arm or leg.
• Pulmonary Embolism (PE): Sudden shortness of breath, chest pain, rapid heart rate, or coughing.
• Stroke: Sudden weakness or numbness on one side of the body, difficulty speaking, severe headache.
• Myocardial Infarction (Heart Attack): Chest pain, shortness of breath, pain radiating to the arm or jaw.

Report any such symptoms to your doctor immediately. Your physician will assess your individual risk factors for thrombosis and monitor you appropriately, especially if you have liver disease, are undergoing surgery, or have other thrombotic risk factors.

3. Development of Inhibitors (Neutralizing Antibodies)

Some patients, particularly those with severe Hemophilia B, may develop neutralizing antibodies (inhibitors) against Factor IX. These inhibitors can bind to and inactivate the infused Idelvion, rendering the treatment ineffective and making bleeding more difficult to control. Signs of inhibitor development include:

• Increased frequency or severity of bleeding episodes.
• Bleeding that does not respond to expected doses of Idelvion.

Patients are regularly monitored for inhibitor development through laboratory tests (e.g., Bethesda assay). If inhibitors are detected, alternative treatment strategies, such as immune tolerance induction (ITI), may be necessary.

Important Precautions and Monitoring

Before initiating and throughout treatment with Idelvion, several precautions and monitoring parameters are crucial for patient safety and efficacy.

Pre-existing Conditions and Risk Factors

Inform your doctor about all your medical conditions, especially:

• Allergies: Any known allergies to albumin, Factor IX products, or any components of Idelvion.
• Liver Disease: Patients with liver disease may have an increased risk of thrombosis.
• Cardiovascular Disease: Pre-existing cardiovascular conditions may increase thrombotic risk.
• History of Inhibitors: Patients who have previously developed Factor IX inhibitors require careful management.

Monitoring Parameters

• Factor IX Activity Levels: Regular monitoring of Factor IX activity is essential to ensure that therapeutic levels are achieved and maintained, especially during prophylaxis or before and after surgery. This guides dose adjustments.
• Inhibitor Screening: Patients should be monitored for the development of Factor IX inhibitors, particularly during the first few months of treatment or if there is an unexpected lack of response to treatment.
• Clinical Monitoring: Observe for signs of bleeding, allergic reactions, or thrombotic events.

Use in Specific Populations

• Pregnancy: There are no adequate and well-controlled studies of Idelvion in pregnant women. Animal studies have not shown evidence of harm, but the potential risks to the fetus are unknown. Idelvion should be used during pregnancy only if clearly needed and the potential benefits outweigh the potential risks.
• Lactation: It is unknown whether Idelvion is excreted in human milk. A decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother.
• Pediatric Use: Idelvion has been studied and is approved for use in pediatric patients (0-17 years) with Hemophilia B. Dosing should be individualized based on age, weight, and Factor IX levels.
• Geriatric Use: Clinical studies included a limited number of patients aged 65 and over. While no overall differences in safety or effectiveness were observed between elderly and younger patients, caution should be exercised due to the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in the elderly.

Drug Interactions

No formal drug interaction studies have been conducted with Idelvion. However, as with any Factor IX product, caution should be exercised when Idelvion is administered concomitantly with other medications that affect coagulation or have a known risk of increasing thrombotic potential. This includes antifibrinolytic agents (e.g., tranexamic acid, epsilon-aminocaproic acid), which can enhance the procoagulant effect and potentially increase the risk of thrombosis when used with Factor IX products. Always inform your doctor and pharmacist about all prescription medications, over-the-counter drugs, supplements, and herbal products you are taking to avoid potential interactions.

Storage and Handling

Proper storage and handling are crucial to maintain the stability, efficacy, and safety of Idelvion.

• Unreconstituted Vials: Store Idelvion vials in their original carton to protect from light. Keep them refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze, as freezing can damage the product. Within its shelf life, Idelvion may be stored at room temperature (up to 30°C or 86°F) for a single period not exceeding 6 months. Once stored at room temperature, it should not be returned to the refrigerator. Note the date when the product is removed from refrigeration.
• Reconstituted Solution: The reconstituted solution should be used immediately. If not used immediately, it must be used within 3 hours after reconstitution. Do not refrigerate the reconstituted solution, and discard any unused portion.

Always check the expiration date on the vial and the diluent. Do not use expired medication, as its potency and safety cannot be guaranteed. Ensure proper disposal of all used syringes, needles, and vials in a puncture-resistant container.

Living Well with Hemophilia B and Idelvion

Managing Hemophilia B is a lifelong journey, and Idelvion plays a crucial role in enabling a better quality of life. Beyond the medication itself, a holistic approach involving patient education, lifestyle modifications, and strong support systems is vital.

Adherence to Treatment

Consistent adherence to your prescribed Idelvion regimen, especially prophylactic infusions, is paramount. Skipping doses can lead to lower Factor IX levels, increasing the risk of spontaneous bleeding and long-term complications. Work closely with your healthcare team to develop a personalized treatment schedule that fits your lifestyle.

Physical Activity and Injury Prevention

While contact sports with a high risk of injury are generally discouraged, regular physical activity is important for maintaining joint health, muscle strength, and overall well-being. Activities like swimming, cycling, and walking are often recommended. Always consult your hematologist before starting any new exercise regimen to ensure it is safe for you. Wearing protective gear (e.g., helmets, knee pads) during activities can further reduce injury risk.

Dental Care

Good oral hygiene and regular dental check-ups are essential. Inform your dentist about your Hemophilia B and Idelvion treatment plan before any procedures. Prophylactic Factor IX infusions may be required before dental extractions or other invasive dental work to prevent excessive bleeding.

Emergency Preparedness

Always carry identification indicating you have Hemophilia B. Have an emergency action plan with your healthcare team, including contact information for your hematologist, emergency services, and instructions for treating a bleed. Ensure you have adequate supplies of Idelvion, especially when traveling.

Psychosocial Support

Living with a chronic condition like Hemophilia B can have emotional and psychological impacts. Connecting with patient advocacy groups, support networks, or mental health professionals can provide valuable support, resources, and a sense of community. Organizations like the National Hemophilia Foundation offer extensive resources for patients and families.

When to See a Doctor

Regular communication with your hematologist or healthcare team is vital for effective Hemophilia B management. You should contact your doctor or seek medical attention in the following situations:

• New or Worsening Bleeding: If you experience a bleeding episode that does not stop or respond to your usual treatment, or if you notice a significant increase in the frequency or severity of bleeding.
• Signs of an Allergic Reaction: Such as hives, widespread rash, difficulty breathing, wheezing, swelling of the face/lips/tongue/throat, or dizziness/fainting during or after an infusion.
• Symptoms of a Blood Clot: Including pain, swelling, warmth, or redness in an arm or leg; sudden shortness of breath; chest pain; or signs of a stroke (sudden numbness/weakness, severe headache, confusion).
• Concerns About Treatment Effectiveness: If you feel Idelvion is not working as expected, if your Factor IX levels are not reaching desired targets, or if breakthrough bleeds are occurring frequently despite prophylaxis.
• Injection Site Issues: If you experience persistent pain, redness, swelling, warmth, or signs of infection (pus, fever) at the infusion site.
• Unexplained Symptoms: Any new or concerning symptoms you experience while on Idelvion, especially if they are severe or unusual.
• Routine Follow-ups: Adhere to your scheduled appointments for monitoring Factor IX levels, inhibitor testing, and overall health assessment. These appointments are crucial for adjusting your treatment plan as needed.

Frequently Asked Questions (FAQs)

Q1: Is Idelvion a cure for Hemophilia B?

No, Idelvion is not a cure for Hemophilia B. It is a replacement therapy that provides the missing Factor IX protein, helping to manage and prevent bleeding episodes. Individuals with Hemophilia B will require lifelong treatment.

Q2: How often is Idelvion administered for prophylaxis?

For routine prophylaxis, Idelvion is typically administered once every 7, 10, or 14 days, depending on individual patient needs, Factor IX levels, and physician recommendations. The extended half-life allows for less frequent infusions compared to older Factor IX products.

Q3: Can children use Idelvion?

Yes, Idelvion is approved for use in both adults and children with Hemophilia B. Dosing for pediatric patients is individualized based on weight, age, and Factor IX levels, carefully determined by a hematologist.

Q4: What should I do if I miss a dose of Idelvion?

If you miss a dose for routine prophylaxis, contact your healthcare provider immediately for guidance. They will advise you on when to take your next dose based on your individual treatment plan and the duration of protection expected from your last dose. Do not double a dose to make up for a missed one.

Q5: Can I travel with Idelvion?

Yes, you can travel with Idelvion. It is important to keep your medication in its original packaging and store it according to the manufacturer's instructions. When traveling by air, always keep your medication in your carry-on luggage to avoid extreme temperatures in checked baggage. It is also advisable to carry a letter from your doctor explaining your need for the medication, especially when crossing international borders, to avoid issues with security or customs.

Q6: Does Idelvion contain human blood products?

No, Idelvion is a recombinant Factor IX product, meaning it is produced using genetically engineered cells and does not contain human blood or plasma. This eliminates the risk of transmitting human blood-borne viruses, which was a historical concern with plasma-derived products.

Q7: What is an inhibitor, and how does it affect Idelvion treatment?

An inhibitor is an antibody developed by the immune system that attacks and neutralizes the infused Factor IX, making the treatment ineffective. If inhibitors develop, Idelvion may no longer work to control bleeding. Your doctor will regularly test for inhibitors, and if detected, alternative treatments or immune tolerance induction (ITI) therapy may be necessary.

Q8: What are the benefits of Idelvion's extended half-life?

The extended half-life of Idelvion allows for less frequent intravenous infusions, typically once every 7, 10, or 14 days for prophylaxis. This offers greater convenience, improves patient adherence to treatment, reduces the burden of frequent injections, and provides more sustained protection against bleeding episodes, thereby enhancing the overall quality of life for individuals with Hemophilia B.

Conclusion

Idelvion represents a significant therapeutic option for individuals living with Hemophilia B. Its innovative extended half-life, achieved through fusion with recombinant albumin, allows for less frequent infusions, thereby enhancing convenience and significantly improving adherence to prophylactic regimens. By effectively replacing deficient Factor IX, Idelvion helps prevent and control bleeding episodes, reducing the risk of joint damage, muscle hematomas, and other severe complications associated with Hemophilia B. While generally well-tolerated, it is crucial for patients and caregivers to be aware of potential side effects, especially hypersensitivity reactions, the rare risk of inhibitor development, or thrombosis. Close collaboration with a hematologist, diligent monitoring of Factor IX levels and inhibitor status, and strict adherence to prescribed dosing schedules are paramount for optimizing treatment outcomes and achieving a better quality of life for those affected by this lifelong condition. Always consult your healthcare provider for personalized advice and comprehensive management of your Hemophilia B treatment plan, ensuring that Idelvion is used safely and effectively as part of a holistic care strategy.

Sources / Medical References

• Healthline. (n.d.). Idelvion (Factor IX (Recombinant), Albumin Fusion Protein). Retrieved from https://www.healthline.com/health/drugs/idelvion
• U.S. Food and Drug Administration (FDA). (n.d.). Idelvion Prescribing Information. Retrieved from official FDA drug labels.
• National Hemophilia Foundation. (n.d.). About Hemophilia B. Retrieved from official NHF resources.
• Biogen. (n.d.). Idelvion (Albutrepenonac alfa). Retrieved from official product website.
• World Federation of Hemophilia. (n.d.). Guidelines for the Management of Hemophilia. Retrieved from official WFH resources.